Particle.news
Download on the App Store
17 ARTICLES
·
2h ago

White House Pauses 100% Drug Tariffs as Trump Unveils TrumpRx and Pfizer Pricing Deal

Officials say the tariff plan is under review, with TrumpRx’s pricing and data practices still undisclosed.

Albert Bourla, chairman and chief executive officer of the pharmaceutical company Pfizer, speaks in the Oval Office of the White House, Tuesday, September 30, 2025, in Washington, as President Donald Trump, right, and Mehmet Oz, Administrator for the Centers for Medicare and Medicaid Services, rear, look on.
Image
Mark Cuban founded his own direct-to-consumer discounted drug company in 2022.
Image

Overview

  • Tariffs that were slated to start Wednesday are on hold, and officials say the 100% levy on certain brand-name imports remains under consideration.
  • Pfizer confirmed participation in TrumpRx with average discounts near 50% and some higher, and the company will extend most‑favored‑nation pricing to Medicaid and guarantee it on new launches.
  • TrumpRx is slated to go live in early 2026, but key operational details and broader manufacturer participation have not been made public.
  • Reports say Pfizer committed about $70 billion to U.S. manufacturing and research in exchange for a three‑year tariff reprieve, though full terms remain confidential.
  • Legal and industry experts warn of unclear data policies and potential disruption to PBMs and specialty pharmacies, and independent pharmacists caution about short‑term access and cost pressures, with benefits likely concentrated among uninsured patients.